Piramal Enterprises Ltd (PEL) has been planning to grow organically in pharmaceutical segment to move up the value chain and expand services like antibody drug conjugates, injectables and drug discovery as per its annual report.

Ajay Piramal, PEL chairman said in the annual report that “Our pharma businesses continue to deliver significant year-on-year growth. Since the Abbott deal, the business has grown at a CAGR of 17 percent. We continue to work towards adding more products to better leverage our global distribution network.”

Read EquityPandit’s Technical Analysis on Nifty Pharma